You are here

  • Home
  • Archive
  • Volume 27, Issue 9
  • Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

Authors

  1. Address correspondence and reprint requests to Karina Dahl Steffensen, MD, PhD, Department of Oncology, Vejle Hospital, Beriderbakken 4, DK-7100 Vejle, Denmark. E-mail: Karina.Dahl.Steffensen{at}rsyd.dk.

Citation

Steffensen KD, Adimi P, Jakobsen A
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study
International Journal of Gynecologic Cancer 2017;27:1842-1849.

Publication history

  • Received April 27, 2017
  • Accepted June 20, 2017
  • First published November 1, 2017.
Online issue publication 
February 27, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.